

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Pipeline Review, H1 2017

https://marketpublishers.com/r/BEB176FBA5EEN.html

Date: June 2017

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: BEB176FBA5EEN

Abstracts

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Pipeline Review, H1 2017

SUMMARY

According to the recently published report 'Bromodomain Containing Protein 3 - Pipeline Review, H1 2017'; Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Bromodomain-containing protein 3 (BRD3) or RING3-like protein (RING3L) is a protein that encodes the BRD3 gene. It plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. It regulates transcription by promoting the binding of the transcription factor GATA1 to its targets.

The report 'Bromodomain Containing Protein 3 - Pipeline Review, H1 2017' outlays comprehensive information on the Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 4 and 3 respectively. Report covers products from



therapy areas Oncology, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Follicular Lymphoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Lymphoma, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)

The report reviews Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics and enlists all their major and minor projects



The report assesses Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Overview

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Companies

Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd

Forma Therapeutics Inc

Incyte Corp

Merck & Co Inc

Nuevolution AB

Resverlogix Corp

Trillium Therapeutics Inc

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Drug Profiles

birabresib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-0610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-54329 - Drug Profile



Product Description

Mechanism Of Action

R&D Progress

NUE-7770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6146 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVX-2135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-281 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEN-3694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Dormant Products

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Discontinued

Products

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Product

Development Milestones

Featured News & Press Releases

Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation

Details at BIO International Convention

Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for

ZEN-3694

Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on

Target 2016

Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and

Corporate Update Webcast Details

Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101

in Advanced Hematological Malignancies



Mar 18, 2015: New Data Investigating Merck's MK-8628 in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015

Nov 12, 2014: Oncoethix Starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)

Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer

Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma Jan 31, 2013: OncoEthix Doses First Patient In Phase I Trial Of OTX015 For Treatment Of Hematologic Malignancies

Nov 29, 2012: Cancer Drug Shows Promise In Eradicating Latent HIV Infection, Research Shows

Nov 21, 2012: Oncoethix Recevies FDA Clearance For Phase I Trial Of OTX015 In Patients With Advanced Hematologic Malignancies

Nov 09, 2012: Oncoethix Reports Preclinical Activity Of OTX015 At 24th EORTX-NCI-AACR Symposium

Aug 16, 2012: Researchers Develop Potential Male Contraceptive Pill Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd.1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd.1), H1 2017

Products under Development by Companies, H1 2017 (Contd.2), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Pipeline by Forma Therapeutics Inc, H1 2017

Pipeline by Incyte Corp, H1 2017

Pipeline by Merck & Co Inc, H1 2017

Pipeline by Nuevolution AB, H1 2017

Pipeline by Resverlogix Corp, H1 2017

Pipeline by Trillium Therapeutics Inc, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017

COMPANIES MENTIONED

F. Hoffmann-La Roche Ltd Forma Therapeutics Inc Incyte Corp Merck & Co Inc Nuevolution AB Resverlogix Corp Trillium Therapeutics Inc



I would like to order

Product name: Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Pipeline Review, H1

2017

Product link: https://marketpublishers.com/r/BEB176FBA5EEN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/BEB176FBA5EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



